Espen Lien1, Guro L Andersen2, Yongde Bao3, Heather Gordish-Dressman4, Jon Skranes5, James A Blackman6, Torstein Vik5. 1. Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Pediatrics, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway. Electronic address: espen.lien@ntnu.no. 2. Vestfold Hospital Trust, The Cerebral Palsy Register of Norway, Tønsberg, Norway. 3. DNA Science Core, Univ. of Virginia School of Medicine, Charlottesville, VA, USA. 4. George Washington University School of Medicine and Health Sciences, Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, USA. 5. Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 6. Department of Pediatrics, University of Virginia, Charlottesville, VA, USA; Cerebral Palsy International Research Foundation, Princeton Junction, NJ, USA.
Abstract
BACKGROUND: The apoE protein is the most important lipid transporter in the brain and has also been shown to have several regulatory functions in the central nervous system. The production of apoE is regulated by a number of genes and increases under certain conditions such as cerebral injury in adults. AIMS: Our aim was to study whether variations in genes regulating the expression of the APOE gene were associated with severity of cerebral palsy (CP). METHODS: Children enrolled in the Cerebral Palsy Register of Norway (CPRN) were invited to participate in this cross-sectional study; 281 of the invited 703 children (40%) returned swabs with buccal cells collected by parents. Six genetic variations thought to affect the production of apoE were genotyped and correlated with clinical data recorded in the CPRN. RESULTS: Compared with children carrying the GG allele, children with genotype GT or TT in a specific genetic variation (rs59007384 located in the nearby TOMM40 gene) had excess risk for worse fine motor function (Odds ratio (OR): 1.82; 95% Confidence interval (CI): 1.10-2.99; p = 0.019) and epilepsy (OR: 2.32; CI: 1.17-4.61; p = 0.016). There was no association between severity of CP and any of the other five genetic variations analyzed. CONCLUSION: Our findings suggest that genetic variations in one of the sequences regulating the expression of APOE, may be associated with worse clinical outcome in children with cerebral palsy.
BACKGROUND: The apoE protein is the most important lipid transporter in the brain and has also been shown to have several regulatory functions in the central nervous system. The production of apoE is regulated by a number of genes and increases under certain conditions such as cerebral injury in adults. AIMS: Our aim was to study whether variations in genes regulating the expression of the APOE gene were associated with severity of cerebral palsy (CP). METHODS:Children enrolled in the Cerebral Palsy Register of Norway (CPRN) were invited to participate in this cross-sectional study; 281 of the invited 703 children (40%) returned swabs with buccal cells collected by parents. Six genetic variations thought to affect the production of apoE were genotyped and correlated with clinical data recorded in the CPRN. RESULTS: Compared with children carrying the GG allele, children with genotype GT or TT in a specific genetic variation (rs59007384 located in the nearby TOMM40 gene) had excess risk for worse fine motor function (Odds ratio (OR): 1.82; 95% Confidence interval (CI): 1.10-2.99; p = 0.019) and epilepsy (OR: 2.32; CI: 1.17-4.61; p = 0.016). There was no association between severity of CP and any of the other five genetic variations analyzed. CONCLUSION: Our findings suggest that genetic variations in one of the sequences regulating the expression of APOE, may be associated with worse clinical outcome in children with cerebral palsy.
Authors: M J Bullido; M J Artiga; M Recuero; I Sastre; M A García; J Aldudo; C Lendon; S W Han; J C Morris; A Frank; J Vázquez; A Goate; F Valdivieso Journal: Nat Genet Date: 1998-01 Impact factor: 38.330
Authors: Espen Lien; Guro L Andersen; Yongde Bao; Heather Gordish-Dressman; Jon S Skranes; Torstein Vik; James A Blackman Journal: Dev Med Child Neurol Date: 2013-02-05 Impact factor: 5.449
Authors: Gai L McMichael; Catherine S Gibson; Paul N Goldwater; Eric A Haan; Kevin Priest; Gustaaf A Dekker; Alastair H MacLennan Journal: Hum Genet Date: 2008-09-23 Impact factor: 4.132
Authors: Lynn M Bekris; Steven P Millard; Nichole M Galloway; Simona Vuletic; John J Albers; Ge Li; Douglas R Galasko; Charles DeCarli; Martin R Farlow; Chris M Clark; Joseph F Quinn; Jeffrey A Kaye; Gerard D Schellenberg; Debby Tsuang; Elaine R Peskind; Chang-En Yu Journal: J Alzheimers Dis Date: 2008-04 Impact factor: 4.472
Authors: Donna S Hurley; Theresa Sukal-Moulton; Deborah Gaebler-Spira; Kristin J Krosschell; Larissa Pavone; Akmer Mutlu; Julius Pa Dewald; Michael E Msall Journal: Int J Phys Med Rehabil Date: 2015-03-23